Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

A Randomized Controlled Trial of a 6-month low carbohydrate intervention on disease progression in men with recurrent prostate cancer: Carbohydrate and Prostate Study 2 (CAPS2).

Freedland SJ, Allen J, Jarman A, Oyekunle T, Armstrong AJ, Moul JW, Sandler H, Posadas EM, Levin D, Wiggins E, Howard LE, Wu Y, Lin PH.

Clin Cancer Res. 2020 Feb 27. pii: clincanres.3873.2019. doi: 10.1158/1078-0432.CCR-19-3873. [Epub ahead of print]

PMID:
32108029
2.

Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure.

Alyamani M, Li J, Patel M, Taylor S, Nakamura F, Berk M, Przybycin C, Posadas EM, Madan RA, Gulley JL, Rini B, Garcia JA, Klein EA, Sharifi N.

Ann Oncol. 2020 Mar;31(3):369-376. doi: 10.1016/j.annonc.2019.12.002. Epub 2020 Feb 11.

PMID:
32057540
3.

Covalent chemistry on nanostructured substrates enables noninvasive quantification of gene rearrangements in circulating tumor cells.

Dong J, Jan YJ, Cheng J, Zhang RY, Meng M, Smalley M, Chen PJ, Tang X, Tseng P, Bao L, Huang TY, Zhou D, Liu Y, Chai X, Zhang H, Zhou A, Agopian VG, Posadas EM, Shyue JJ, Jonas SJ, Weiss PS, Li M, Zheng G, Yu HH, Zhao M, Tseng HR, Zhu Y.

Sci Adv. 2019 Jul 31;5(7):eaav9186. doi: 10.1126/sciadv.aav9186. eCollection 2019 Jul.

4.

A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.

Jan YJ, Yoon J, Chen JF, Teng PC, Yao N, Cheng S, Lozano A, Chu GCY, Chung H, Lu YT, Chen PJ, Wang JJ, Lee YT, Kim M, Zhu Y, Knudsen BS, Feng FY, Garraway IP, Gao AC, Chung LWK, Freeman MR, You S, Tseng HR, Posadas EM.

Theranostics. 2019 Apr 13;9(10):2812-2826. doi: 10.7150/thno.34485. eCollection 2019.

5.

Brain Metastases in Renal Cell Carcinoma: Immunotherapy Responsiveness Is Multifactorial and Heterogeneous.

Reed JP, Posadas EM, Figlin RA.

J Clin Oncol. 2019 Aug 10;37(23):1987-1989. doi: 10.1200/JCO.19.00639. Epub 2019 Jun 20. No abstract available.

PMID:
31232668
6.

Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma.

Adashek JJ, Salgia MM, Posadas EM, Figlin RA, Gong J.

Clin Genitourin Cancer. 2019 Jun;17(3):e454-e460. doi: 10.1016/j.clgc.2019.01.004. Epub 2019 Jan 15. Review.

PMID:
30733185
7.

Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma.

Reed JP, Posadas EM, Figlin RA.

Expert Rev Anticancer Ther. 2019 Mar;19(3):259-271. doi: 10.1080/14737140.2019.1573678. Epub 2019 Feb 4. Review.

PMID:
30669895
8.

Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas.

Zhao SG, Chen WS, Das R, Chang SL, Tomlins SA, Chou J, Quigley DA, Dang HX, Barnard TJ, Mahal BA, Gibb EA, Liu Y, Davicioni E, Duska LR, Posadas EM, Jolly S, Spratt DE, Nguyen PL, Maher CA, Small EJ, Feng FY.

Clin Cancer Res. 2019 Apr 15;25(8):2450-2457. doi: 10.1158/1078-0432.CCR-18-3121. Epub 2018 Dec 20.

PMID:
30573691
9.

An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma.

Choueiri TK, Michaelson MD, Posadas EM, Sonpavde GP, McDermott DF, Nixon AB, Liu Y, Yuan Z, Seon BK, Walsh M, Jivani MA, Adams BJ, Theuer CP.

Oncologist. 2019 Feb;24(2):202-210. doi: 10.1634/theoncologist.2018-0299. Epub 2018 Sep 6.

10.

Emerin Deregulation Links Nuclear Shape Instability to Metastatic Potential.

Reis-Sobreiro M, Chen JF, Novitskaya T, You S, Morley S, Steadman K, Gill NK, Eskaros A, Rotinen M, Chu CY, Chung LWK, Tanaka H, Yang W, Knudsen BS, Tseng HR, Rowat AC, Posadas EM, Zijlstra A, Di Vizio D, Freeman MR.

Cancer Res. 2018 Nov 1;78(21):6086-6097. doi: 10.1158/0008-5472.CAN-18-0608. Epub 2018 Aug 28.

11.

Large extracellular vesicles carry most of the tumour DNA circulating in prostate cancer patient plasma.

Vagner T, Spinelli C, Minciacchi VR, Balaj L, Zandian M, Conley A, Zijlstra A, Freeman MR, Demichelis F, De S, Posadas EM, Tanaka H, Di Vizio D.

J Extracell Vesicles. 2018 Aug 7;7(1):1505403. doi: 10.1080/20013078.2018.1505403. eCollection 2018.

12.

Circulating monocytes from prostate cancer patients promote invasion and motility of epithelial cells.

Cavassani KA, Meza RJ, Habiel DM, Chen JF, Montes A, Tripathi M, Martins GA, Crother TR, You S, Hogaboam CM, Bhowmick N, Posadas EM.

Cancer Med. 2018 Sep;7(9):4639-4649. doi: 10.1002/cam4.1695. Epub 2018 Aug 9.

13.

Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming.

Mishra R, Haldar S, Placencio V, Madhav A, Rohena-Rivera K, Agarwal P, Duong F, Angara B, Tripathi M, Liu Z, Gottlieb RA, Wagner S, Posadas EM, Bhowmick NA.

J Clin Invest. 2018 Oct 1;128(10):4472-4484. doi: 10.1172/JCI99397. Epub 2018 Jul 26.

14.

Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.

Autio KA, Dreicer R, Anderson J, Garcia JA, Alva A, Hart LL, Milowsky MI, Posadas EM, Ryan CJ, Graf RP, Dittamore R, Schreiber NA, Summa JM, Youssoufian H, Morris MJ, Scher HI.

JAMA Oncol. 2018 Oct 1;4(10):1344-1351. doi: 10.1001/jamaoncol.2018.2168.

15.

Structure and function analysis in circulating tumor cells: using nanotechnology to study nuclear size in prostate cancer.

Yao N, Jan YJ, Cheng S, Chen JF, Chung LW, Tseng HR, Posadas EM.

Am J Clin Exp Urol. 2018 Apr 1;6(2):43-54. eCollection 2018. Review.

16.

NanoVelcro rare-cell assays for detection and characterization of circulating tumor cells.

Jan YJ, Chen JF, Zhu Y, Lu YT, Chen SH, Chung H, Smalley M, Huang YW, Dong J, Chen LC, Yu HH, Tomlinson JS, Hou S, Agopian VG, Posadas EM, Tseng HR.

Adv Drug Deliv Rev. 2018 Feb 1;125:78-93. doi: 10.1016/j.addr.2018.03.006. Epub 2018 Mar 15. Review.

17.

Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate.

Salem AF, Wang S, Billet S, Chen JF, Udompholkul P, Gambini L, Baggio C, Tseng HR, Posadas EM, Bhowmick NA, Pellecchia M.

J Med Chem. 2018 Mar 8;61(5):2052-2061. doi: 10.1021/acs.jmedchem.7b01837. Epub 2018 Feb 27.

18.

Modulation of cabozantinib efficacy by the prostate tumor microenvironment.

Tripathi M, Nandana S, Billet S, Cavassani KA, Mishra R, Chung LWK, Posadas EM, Bhowmick NA.

Oncotarget. 2017 Sep 23;8(50):87891-87902. doi: 10.18632/oncotarget.21248. eCollection 2017 Oct 20.

19.

S-adenosylmethionine and methylthioadenosine inhibit cancer metastasis by targeting microRNA 34a/b-methionine adenosyltransferase 2A/2B axis.

Tomasi ML, Cossu C, Spissu Y, Floris A, Ryoo M, Iglesias-Ara A, Wang Q, Pandol SJ, Bhowmick NA, Seki E, Posadas EM, Lu SC.

Oncotarget. 2017 Aug 12;8(45):78851-78869. doi: 10.18632/oncotarget.20234. eCollection 2017 Oct 3.

20.

Glycan Stimulation Enables Purification of Prostate Cancer Circulating Tumor Cells on PEDOT NanoVelcro Chips for RNA Biomarker Detection.

Shen MY, Chen JF, Luo CH, Lee S, Li CH, Yang YL, Tsai YH, Ho BC, Bao LR, Lee TJ, Jan YJ, Zhu YZ, Cheng S, Feng FY, Chen P, Hou S, Agopian V, Hsiao YS, Tseng HR, Posadas EM, Yu HH.

Adv Healthc Mater. 2018 Feb;7(3). doi: 10.1002/adhm.201700701. Epub 2017 Sep 11.

21.

In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database.

Whitney CA, Howard LE, Posadas EM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ.

Eur Urol Focus. 2017 Oct;3(4-5):480-486. doi: 10.1016/j.euf.2016.08.007. Epub 2016 Aug 29.

PMID:
28753787
22.

Targeted therapies for renal cell carcinoma.

Posadas EM, Limvorasak S, Figlin RA.

Nat Rev Nephrol. 2017 Aug;13(8):496-511. doi: 10.1038/nrneph.2017.82. Epub 2017 Jul 10. Review.

PMID:
28691713
23.

MAOA-Dependent Activation of Shh-IL6-RANKL Signaling Network Promotes Prostate Cancer Metastasis by Engaging Tumor-Stromal Cell Interactions.

Wu JB, Yin L, Shi C, Li Q, Duan P, Huang JM, Liu C, Wang F, Lewis M, Wang Y, Lin TP, Pan CC, Posadas EM, Zhau HE, Chung LWK.

Cancer Cell. 2017 Mar 13;31(3):368-382. doi: 10.1016/j.ccell.2017.02.003.

24.

Circulating tumor cells in prostate cancer: beyond enumeration.

Chen JF, Lu YT, Cheng S, Tseng HR, Figlin RA, Posadas EM.

Clin Adv Hematol Oncol. 2017 Jan;15(1):63-73.

PMID:
28212371
25.

MYC Mediates Large Oncosome-Induced Fibroblast Reprogramming in Prostate Cancer.

Minciacchi VR, Spinelli C, Reis-Sobreiro M, Cavallini L, You S, Zandian M, Li X, Mishra R, Chiarugi P, Adam RM, Posadas EM, Viglietto G, Freeman MR, Cocucci E, Bhowmick NA, Di Vizio D.

Cancer Res. 2017 May 1;77(9):2306-2317. doi: 10.1158/0008-5472.CAN-16-2942. Epub 2017 Feb 15. Erratum in: Cancer Res. 2017 Jul 15;77(14 ):3961.

26.

Recent Advances in the Medical Treatment of Recurrent or Metastatic Renal Cell Cancer.

Kumbla RA, Figlin RA, Posadas EM.

Drugs. 2017 Jan;77(1):17-28. doi: 10.1007/s40265-016-0665-1. Review.

PMID:
27995579
27.

Applications of circulating tumor cells for prostate cancer.

Cheng S, Chen JF, Lu YT, Chung LWK, Tseng HR, Posadas EM.

Asian J Urol. 2016 Oct;3(4):254-259. doi: 10.1016/j.ajur.2016.09.004. Epub 2016 Sep 14. Review.

28.

Cultured circulating tumor cells and their derived xenografts for personalized oncology.

Wang R, Chu GCY, Mrdenovic S, Annamalai AA, Hendifar AE, Nissen NN, Tomlinson JS, Lewis M, Palanisamy N, Tseng HR, Posadas EM, Freeman MR, Pandol SJ, Zhau HE, Chung LWK.

Asian J Urol. 2016 Oct;3(4):240-253. doi: 10.1016/j.ajur.2016.08.005. Epub 2016 Aug 25. Review.

29.

Biology and therapy of urological cancer metastasis.

Posadas EM, McConkey DJ, Chung LWK.

Asian J Urol. 2016 Oct;3(4):167-169. doi: 10.1016/j.ajur.2016.09.008. Epub 2016 Sep 23. No abstract available.

30.

Third-Line Treatment Options for Kidney Cancer.

Posadas EM, Limvorasak S, Figlin RA.

Oncology (Williston Park). 2016 Sep 15;30(9):813-5. No abstract available.

31.

Clinical Applications of NanoVelcro Rare-Cell Assays for Detection and Characterization of Circulating Tumor Cells.

Chen JF, Zhu Y, Lu YT, Hodara E, Hou S, Agopian VG, Tomlinson JS, Posadas EM, Tseng HR.

Theranostics. 2016 Jun 15;6(9):1425-39. doi: 10.7150/thno.15359. eCollection 2016. Review.

32.

Personalized Therapeutics and Value in Renal Cell Carcinoma: Moving Beyond Lines of Therapy.

Posadas EM, Figlin RA.

J Oncol Pract. 2016 May;12(5):424-5. doi: 10.1200/JOP.2016.012393. No abstract available.

PMID:
27170689
33.

Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.

Tagawa ST, Posadas EM, Bruce J, Lim EA, Petrylak DP, Peng W, Kheoh T, Maul S, Smit JW, Gonzalez MD, De Porre P, Tran N, Nanus DM.

Eur Urol. 2016 Nov;70(5):718-721. doi: 10.1016/j.eururo.2016.01.028. Epub 2016 Feb 3.

PMID:
26852075
34.

SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.

Gururajan M, Cavassani KA, Sievert M, Duan P, Lichterman J, Huang JM, Smith B, You S, Nandana S, Chu GC, Mink S, Josson S, Liu C, Morello M, Jones LW, Kim J, Freeman MR, Bhowmick N, Zhau HE, Chung LW, Posadas EM.

Oncotarget. 2015 Dec 29;6(42):44072-83. doi: 10.18632/oncotarget.6398.

35.

A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer.

Jiang R, Lu YT, Ho H, Li B, Chen JF, Lin M, Li F, Wu K, Wu H, Lichterman J, Wan H, Lu CL, OuYang W, Ni M, Wang L, Li G, Lee T, Zhang X, Yang J, Rettig M, Chung LW, Yang H, Li KC, Hou Y, Tseng HR, Hou S, Xu X, Wang J, Posadas EM.

Oncotarget. 2015 Dec 29;6(42):44781-93. doi: 10.18632/oncotarget.6330.

36.

Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study.

Posadas EM, Ahmed RS, Karrison T, Szmulewitz RZ, O'Donnell PH, Wade JL 3rd, Shen J, Gururajan M, Sievert M, Stadler WM.

Prostate. 2016 Feb 15;76(3):286-93. doi: 10.1002/pros.23119. Epub 2015 Oct 23.

37.

Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.

Hanyok BT, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Posadas EM, Freedland SJ.

Cancer. 2016 Jan 15;122(2):222-9. doi: 10.1002/cncr.29748. Epub 2015 Oct 20.

38.

Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity.

Hahn NM, Knudsen BS, Daneshmand S, Koch MO, Bihrle R, Foster RS, Gardner TA, Cheng L, Liu Z, Breen T, Fleming MT, Lance R, Corless CL, Alva AS, Shen SS, Huang F, Gertych A, Gallick GE, Mallick J, Ryan C, Galsky MD, Lerner SP, Posadas EM, Sonpavde G.

Urol Oncol. 2016 Jan;34(1):4.e11-7. doi: 10.1016/j.urolonc.2015.08.005. Epub 2015 Sep 9.

PMID:
26362343
39.

Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases.

Chen JF, Ho H, Lichterman J, Lu YT, Zhang Y, Garcia MA, Chen SF, Liang AJ, Hodara E, Zhau HE, Hou S, Ahmed RS, Luthringer DJ, Huang J, Li KC, Chung LW, Ke Z, Tseng HR, Posadas EM.

Cancer. 2015 Sep 15;121(18):3240-51. doi: 10.1002/cncr.29455. Epub 2015 May 14.

40.

miR-154* and miR-379 in the DLK1-DIO3 microRNA mega-cluster regulate epithelial to mesenchymal transition and bone metastasis of prostate cancer.

Gururajan M, Josson S, Chu GC, Lu CL, Lu YT, Haga CL, Zhau HE, Liu C, Lichterman J, Duan P, Posadas EM, Chung LW.

Clin Cancer Res. 2014 Dec 15;20(24):6559-69. doi: 10.1158/1078-0432.CCR-14-1784. Epub 2014 Oct 16.

41.

Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis.

Josson S, Gururajan M, Sung SY, Hu P, Shao C, Zhau HE, Liu C, Lichterman J, Duan P, Li Q, Rogatko A, Posadas EM, Haga CL, Chung LW.

Oncogene. 2015 May 21;34(21):2690-9. doi: 10.1038/onc.2014.212. Epub 2014 Jul 28.

PMID:
25065597
42.

miR-409-3p/-5p promotes tumorigenesis, epithelial-to-mesenchymal transition, and bone metastasis of human prostate cancer.

Josson S, Gururajan M, Hu P, Shao C, Chu GY, Zhau HE, Liu C, Lao K, Lu CL, Lu YT, Lichterman J, Nandana S, Li Q, Rogatko A, Berel D, Posadas EM, Fazli L, Sareen D, Chung LW.

Clin Cancer Res. 2014 Sep 1;20(17):4636-46. doi: 10.1158/1078-0432.CCR-14-0305. Epub 2014 Jun 24.

43.

Kidney cancer: progress and controversies in neoadjuvant therapy.

Posadas EM, Figlin RA.

Nat Rev Urol. 2014 May;11(5):254-5. doi: 10.1038/nrurol.2014.89. Epub 2014 Apr 22.

PMID:
24752207
44.

Detection of live circulating tumor cells by a class of near-infrared heptamethine carbocyanine dyes in patients with localized and metastatic prostate cancer.

Shao C, Liao CP, Hu P, Chu CY, Zhang L, Bui MH, Ng CS, Josephson DY, Knudsen B, Tighiouart M, Kim HL, Zhau HE, Chung LW, Wang R, Posadas EM.

PLoS One. 2014 Feb 14;9(2):e88967. doi: 10.1371/journal.pone.0088967. eCollection 2014.

45.

Targeting angiogenesis in renal cell carcinoma.

Posadas EM, Limvorasak S, Sharma S, Figlin RA.

Expert Opin Pharmacother. 2013 Nov;14(16):2221-36. doi: 10.1517/14656566.2013.832202. Epub 2013 Aug 28. Review.

PMID:
23984807
46.

NanoVelcro Chip for CTC enumeration in prostate cancer patients.

Lu YT, Zhao L, Shen Q, Garcia MA, Wu D, Hou S, Song M, Xu X, Ouyang WH, Ouyang WW, Lichterman J, Luo Z, Xuan X, Huang J, Chung LW, Rettig M, Tseng HR, Shao C, Posadas EM.

Methods. 2013 Dec 1;64(2):144-52. doi: 10.1016/j.ymeth.2013.06.019. Epub 2013 Jun 29.

47.

High-purity prostate circulating tumor cell isolation by a polymer nanofiber-embedded microchip for whole exome sequencing.

Zhao L, Lu YT, Li F, Wu K, Hou S, Yu J, Shen Q, Wu D, Song M, OuYang WH, Luo Z, Lee T, Fang X, Shao C, Xu X, Garcia MA, Chung LW, Rettig M, Tseng HR, Posadas EM.

Adv Mater. 2013 Jun 4;25(21):2897-902. doi: 10.1002/adma.201205237. Epub 2013 Mar 26.

48.

A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.

Antonarakis ES, Heath EI, Posadas EM, Yu EY, Harrison MR, Bruce JY, Cho SY, Wilding GE, Fetterly GJ, Hangauer DG, Kwan MF, Dyster LM, Carducci MA.

Cancer Chemother Pharmacol. 2013 Apr;71(4):883-92. doi: 10.1007/s00280-013-2079-z. Epub 2013 Jan 13.

49.

Understanding the role of MET kinase in cancer therapy.

Posadas EM, Figlin RA.

J Clin Oncol. 2013 Jan 10;31(2):169-70. doi: 10.1200/JCO.2012.46.7738. Epub 2012 Dec 3. No abstract available.

PMID:
23213104
50.

Future perspectives of prostate cancer therapy.

Gururajan M, Posadas EM, Chung LW.

Transl Androl Urol. 2012 Jan 3;1(1):19-32.

Supplemental Content

Loading ...
Support Center